NCT04426292

SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 3,500 (estimated)
• Sponsor: Universitair Ziekenhuis Brussel · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus rapidly spread to the rest of the world, including Europe and explicitly affects the respiratory system, generating Coronavirus disease 2019 (COVID-19). This study is a monocentric interventional prospective cohort study. After signing a written informed consent, participants will be recruited for questionnaire completion and blood sampling. Sample storage and analysis will be performed at the laboratory of microbiology of the UZ Brussel. * To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5. * To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months.

Conditions

• Sars-CoV2

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Serological testing	Antibody testing for Sars-COV-2 antibodies in blood.

Timeline

• Start date: 2020-05-12
• Primary completion: 2021-12-23
• Completion: 2021-12-25
• First posted: 2020-06-11
• Last updated: 2021-11-04

Locations

1 site across 1 country: Belgium